X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1079) 1079
Newsletter (66) 66
Publication (65) 65
Newspaper Article (20) 20
Book Review (15) 15
Magazine Article (9) 9
Book Chapter (8) 8
Dissertation (4) 4
Web Resource (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aprepitant (1001) 1001
humans (560) 560
index medicus (519) 519
nausea (426) 426
chemotherapy (415) 415
oncology (415) 415
cancer (368) 368
prevention (349) 349
double-blind (343) 343
female (341) 341
vomiting (316) 316
male (308) 308
vomiting - chemically induced (299) 299
nausea - chemically induced (291) 291
middle aged (279) 279
antiemetics - therapeutic use (271) 271
dexamethasone (253) 253
adult (244) 244
placebo-controlled trial (228) 228
vomiting - prevention & control (220) 220
antineoplastic agents - adverse effects (215) 215
nausea - prevention & control (206) 206
aged (203) 203
pharmacology & pharmacy (202) 202
morpholines - therapeutic use (185) 185
palonosetron (172) 172
medicine & public health (170) 170
moderately emetogenic chemotherapy (170) 170
research (161) 161
chemotherapy-induced nausea (160) 160
antagonist aprepitant (159) 159
chemotherapy-induced nausea and vomiting (151) 151
efficacy (143) 143
ondansetron (138) 138
high-dose cisplatin (135) 135
neoplasms - drug therapy (135) 135
antiemetics (134) 134
care and treatment (128) 128
health care sciences & services (124) 124
antiemetics - administration & dosage (116) 116
nausea - drug therapy (116) 116
vomiting - drug therapy (116) 116
cisplatin (115) 115
treatment outcome (113) 113
nursing (112) 112
analysis (110) 110
morpholines - administration & dosage (110) 110
neurokinin-1 receptor antagonists (109) 109
rehabilitation (109) 109
complications and side effects (105) 105
pain medicine (100) 100
double-blind method (99) 99
induced nausea (96) 96
drug therapy (95) 95
drug therapy, combination (95) 95
emesis (94) 94
rehabilitation medicine (91) 91
receptor antagonist (90) 90
health aspects (89) 89
gastrointestinal agents (87) 87
antineoplastic combined chemotherapy protocols - adverse effects (86) 86
morpholines - pharmacology (86) 86
cinv (85) 85
dexamethasone - therapeutic use (83) 83
dosage and administration (82) 82
risk factors (79) 79
animals (78) 78
pharmacokinetics (78) 78
substance p (78) 78
cisplatin-induced emesis (75) 75
prospective studies (73) 73
fosaprepitant (71) 71
cisplatin - adverse effects (69) 69
dexamethasone - administration & dosage (68) 68
patients (68) 68
phase-iii (67) 67
cancer therapies (66) 66
substance-p (66) 66
antiemetics - adverse effects (65) 65
antineoplastic agents - therapeutic use (65) 65
clinical trials (65) 65
antineoplastic combined chemotherapy protocols - therapeutic use (64) 64
cancer patients (64) 64
receptor antagonist aprepitant (64) 64
young adult (64) 64
delayed emesis (62) 62
prophylaxis (62) 62
antiemetic (61) 61
antiemetics - pharmacology (61) 61
morpholines - adverse effects (60) 60
nursing management/nursing research (60) 60
therapy (60) 60
granisetron (59) 59
aged, 80 and over (58) 58
quality of life (55) 55
olanzapine (54) 54
safety (53) 53
adolescent (51) 51
breast cancer (51) 51
induced emesis (51) 51
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1133) 1133
German (12) 12
Japanese (9) 9
French (8) 8
Spanish (6) 6
Korean (4) 4
Czech (2) 2
Russian (2) 2
Chinese (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 01/2018, Volume 154, Issue 1, pp. 65 - 76.e11
Journal Article
Chinese Journal of Lung Cancer, ISSN 1009-3419, 2018, Volume 21, Issue 10, pp. 800 - 804
Journal Article
American Journal of Health-System Pharmacy, ISSN 1079-2082, 12/2017, Volume 74, Issue 24, p. 2026
Journal Article
Indian Journal of Medical and Paediatric Oncology, ISSN 0971-5851, 04/2019, Volume 40, Issue 2, pp. 279 - 281
Once you decide to walk on an adventurous path, you need to follow the process stated below: ·Make a resolve ·Seek guidance ·Practice ·Final preparation for... 
Aprepitant | Coronary artery bypass | Marathons
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 05/2016, Volume 43, Issue 5, pp. 583 - 586
Journal Article
WHO Drug Information, ISSN 1010-9609, 09/2018, Volume 32, Issue 4, p. 556
Journal Article
International Journal of Biochemistry and Cell Biology, ISSN 1357-2725, 10/2018, Volume 103, pp. 105 - 114
While a batch of efforts are fastened on synthesizing the novel targeted anti-cancer agents, recent investigations have achieved a breakthrough in identifying... 
Aprepitant | Acute leukemia | NF-κB | Arsenic trioxide | Neurokinin-1 receptor | LYMPHOBLASTIC-LEUKEMIA CELLS | APOPTOSIS | ANTAGONIST APREPITANT | CHEMOTHERAPY-INDUCED NAUSEA | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | NK-1 RECEPTOR | C-MYC | DEATH | CANCER | CELL BIOLOGY | NF-kappa B | SUBSTANCE-P
Journal Article
Current Problems in Cancer, ISSN 0147-0272, 2019, p. 100462
Objective: To assess the safety and efficacy of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline chemotherapy-induced... 
Aprepitant | CINV | Anthracycline | Multiple-day chemotherapy
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 5, pp. 863 - 868
Aprepitant is a known inducer of CYP2C9, the main warfarin-metabolizing enzyme. Consequently, co-administration of these two drugs may result in reduction of... 
Journal Article
Journal Article
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, ISSN 0306-5251, 03/2018, Volume 84, Issue 3, pp. 604 - 604
Journal Article
Peptides, ISSN 0196-9781, 09/2012, Volume 37, Issue 1, pp. 86 - 97
The novel NK receptor ligand Netupitant has been characterized in vitro and in vivo. In calcium mobilization studies CHO cells expressing the human NK... 
Aprepitant | Calcium mobilization | Guinea pig ileum | Gerbils | Mice | Netupitant
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016
Aprepitant is a known inducer of CYP2C9, the main warfarin-metabolizing enzyme. Consequently, co-administration of these two drugs may result in reduction of... 
CYP2C9 | aprepitant | drug-drug interaction | chemotherapy | warfarin
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 2016, Volume 791, pp. 274 - 283
Increasing number of genetic and cancer biology studies indicated a prominent role for tachykinin NK receptor (NK R) in cancer cell growth and survival.... 
Aprepitant | receptor | Acute lymphoblastic leukemia | Nalm-6 cells | Tachykinin NK | P53
Journal Article
EUROPEAN JOURNAL OF PHARMACOLOGY, ISSN 0014-2999, 11/2016, Volume 791, pp. 274 - 283
Increasing number of genetic and cancer biology studies indicated a prominent role for tachykinin NK1 receptor (Will) in cancer cell growth and survival.... 
Aprepitant | TARGET | ANTAGONIST APREPITANT | NK-1 RECEPTOR | NEUROKININ-1 RECEPTOR | P53 | Tachykinin NK1 receptor | MELANOMA | Acute lymphoblastic leukemia | alm-6 cells | ANTITUMOR ACTION | GROWTH | PHARMACOLOGY & PHARMACY | P53 N | NF-KAPPA-B | EXPRESSION
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 10/2018, Volume 65, Issue 10, pp. e27273 - n/a
Background This was a subgroup analysis of age group, dexamethasone use, and very highly emetogenic chemotherapy (VHEC) use from a randomised, multicentre,... 
paediatrics | adolescent | aprepitant | cancer | anti‐emetics | child | anti-emetics | ANTAGONIST APREPITANT | EFFICACY | ONCOLOGY | TOLERABILITY | DOUBLE-BLIND | PEDIATRICS | PLACEBO-CONTROLLED TRIAL | HEMATOLOGY | Prevention | Pediatrics | Chemotherapy | Dexamethasone | Gastrointestinal agents | Analysis | Nausea | Cancer | Vomiting | Secondary analysis | Age | Subgroups
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.